Defining the role of GLP-1 receptor agonists for individualized treatment of type 2 diabetes (original) (raw)

Incretin-Based Therapies for Type 2 Diabetes Mellitus: Properties, Functions, and Clinical Implications

Melva Louisa

The American Journal of Medicine, 2011

View PDFchevron_right

Incretin mimetics and dipeptidyl peptidase-4 inhibitors: innovative treatment therapies for type 2 diabetes

Jaime Davidson

Arquivos Brasileiros de Endocrinologia & Metabologia, 2008

View PDFchevron_right

The Incretin Approach for Diabetes Treatment: Modulation of Islet Hormone Release by GLP-1 Agonism

Jens Juul Holst

Diabetes, 2004

View PDFchevron_right

GLP-1 receptor agonists in the treatment of type 2 diabetes: role and clinical experience to date

Stephen Brunton

Postgraduate Medicine

View PDFchevron_right

Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?

Stephen Gutkin

European Journal of Endocrinology, 2008

View PDFchevron_right

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium

Michael Horowitz, Joan Khoo

Therapeutics and Clinical Risk Management

View PDFchevron_right

Incretin-based Therapies (Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors) for the Treatment of Type 2 Diabetes

Jean-françois Yale

Canadian Journal of Diabetes, 2012

View PDFchevron_right

Incretin-Based Therapies in Type 2 Diabetes Mellitus

chee keong Chia

The Journal of Clinical Endocrinology & Metabolism, 2008

View PDFchevron_right

Incorporating Incretin-Based Therapies Into Clinical Practice: Differences Between Glucagon-Like Peptide 1 Receptor Agonists and Dipeptidyl Peptidase 4 Inhibitors

Jaime Davidson

Mayo Clinic Proceedings, 2010

View PDFchevron_right

Incretin based therapies for type 2 diabetes mellitus

Tarik Elhadd

Journal of the Indian Medical Association, 2008

View PDFchevron_right

Current Issues in GLP-1 Receptor Agonist Therapy for Type 2 Diabetes

Zachary Bloomgarden, Carol Wysham

Endocrine Practice, 2012

View PDFchevron_right

Incretin-based therapies: focus on effects beyond glycemic control alone

Jaime Davidson

Diabetes therapy : research, treatment and education of diabetes and related disorders, 2013

View PDFchevron_right

Incretins: Their physiology and application in the treatment of diabetes mellitus

Hasan Altunbas

Diabetes/Metabolism Research and Reviews, 2014

View PDFchevron_right

Defining the Role of GLP-1 in the Enteroinsulinar Axis in Type 2 Diabetes Using DPP-4 Inhibition and GLP-1 Receptor Blockade

Jens J U U L Holst

Diabetes, 2014

View PDFchevron_right

Incretin System: Recent Advances in Glucagon Like Peptide-1 and Dipeptidyl Peptidase-4 Inhibitors

Dr Rameshwar Mahaseth

Journal of Patan Academy of Health Sciences, 2015

View PDFchevron_right

An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists

Krystal Edwards

Diabetes Technology & Therapeutics, 2012

View PDFchevron_right

Beyond glucose: cardiovascular effects of incretins and dipeptidyl peptidase-4 substrates

Franca Stedile Angeli

European Heart Journal Supplements, 2012

View PDFchevron_right

Effects of Incretin Mimetic Drugs on Diabetic Cardiovascular Functions

ebru inan

2017

View PDFchevron_right

Medicinal Chemistry and Applications of Incretins and DPP-4 Inhibitors in the Treatment of Type 2 Diabetes Mellitus

Kornelia Tekes

The open medicinal chemistry journal, 2011

View PDFchevron_right

Adapting the GLP-1-Signaling System to the Treatment of Type 2 Diabetes

Domenico Cozzolino

Current Diabetes Reviews, 2007

View PDFchevron_right

Management of type 2 diabetes: the GLP-1 pathway

Abd Tahrani

Future Prescriber, 2008

View PDFchevron_right

From Theory to Clinical Practice in the Use of GLP-1 Receptor Agonists and DPP-4 Inhibitors Therapy

Carlo Rotella

Experimental Diabetes Research, 2011

View PDFchevron_right

GLP-1 based therapy for type 2 diabetes

Bernard Portha

European Journal of Pharmaceutical Sciences, 2006

View PDFchevron_right

The incretin system and its role in type 2 diabetes mellitus

Jens Juul Holst

Molecular and Cellular Endocrinology, 2009

View PDFchevron_right

Glucagon-like peptide 1 and inhibitors of dipeptidyl peptidase IV in the treatment of type 2 diabetes mellitus

Jens Juul Holst

Current Opinion in Pharmacology, 2004

View PDFchevron_right

Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes

S. Choukem

Diabetes & Metabolism, 2008

View PDFchevron_right

Incretins: Beyond type 2 diabetes

Paresh Dandona

Diabetes, Obesity and Metabolism

View PDFchevron_right

Exploiting the pleiotropic actions of GLP-1 for the management of type 2 diabetes mellitus and its complications

Luigi Laviola

Diabetes Research and Clinical Practice, 2007

View PDFchevron_right

An Overview of Incretin-Based Therapies: Pharmacology and Future Perspectives

Gehan Heeba

Bulletin of Pharmaceutical Sciences. Assiut

View PDFchevron_right

Glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase IV inhibitors: new therapeutic agents for the treatment of type 2 diabetes

Owais Khan

Current Opinion in Endocrinology & Diabetes, 2005

View PDFchevron_right

Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1

Jens Juul Holst

Diabetes/Metabolism Research and Reviews, 2002

View PDFchevron_right

Secretion of glucagon- like peptide-1 (GLP-1) in type 2 diabetic patients: Study of its relation to glucose lowering effect of dipeptidyl peptidase IV (DPP-IV) inhibitors.

Rizk Sarhan

View PDFchevron_right

Review Article Advances in pharmacotherapy of Type-2 diabetes (Part-2: The incretin mimetics)

Tarik Elhadd

Sudan medical journal

View PDFchevron_right

GLP-1 receptor agonists for type 2 diabetes

Luc Van Gaal

The Lancet, 2009

View PDFchevron_right